Careers  |  Sign In  |  Register

Sorafenib Did Not Improve RFS in mRCC After Radical Resection


In the largest prospective study of angiogenesis in metastatic renal cell carcinoma (mRCC) patients to date, an Italian study yielded data that suggests sorafenib had no meaningful impact in patient recovery. Approved for the treatment of RCC, sorafenib was administered following a radical metastectomy, and showed no meaningful change to median recurrence-free survival (RFS). The results of the study were presented at the 2018 American Society of Clinical Oncology annual meeting.

Learn more by clicking here.